MicroRNA-101 and MicroRNA-122 in different clinical entities of hepatitis B virus infection in Iraq | ||||
| Microbes and Infectious Diseases | ||||
| Articles in Press, Accepted Manuscript, Available Online from 12 May 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mid.2025.377262.2721 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mustafa MAHMUD MUSTAF BADRANI   1; Müge FIRAT 2; Abdulrazak Hasan 3
| ||||
| 1Iraqi Ministry of Health - Diyala Health Directorate, Iraq. | ||||
| 2Şabanözü Vocational High School, Veterinary Department, 2Çankırı Karatekin University, TURKEY | ||||
| 3College of Science, Diyala University-IRAQ | ||||
| Abstract | ||||
| Background: Hepatitis B virus (HBV) infection is a huge economic and public health burden across the globe. The abnormal expression of microRNAs (miRNAs) has a significant influence on a variety of pathological situations. Objectives: The purpose of this study was to investigate the diagnostic and prognostic utility and reliability of miRNAs (MiR122 and MiR101) for HBV infection and its chronic consequences. Material and Methods: A case control study, 100 subjects were included as follows: 25 patients as chronic HBV carriers, 25 patients with past Hepatitis B virus infection who were under continued treatment, 25 patients with occult HBV infection. The study was conducted in Baquba Teaching Hospital and the main blood bank in Diyala. Baquba City, the center of Diyala province and extended from July/ 2022 to May/2024. Blood samples were collected before any treatment except with the third group (Under medication). Five ml of blood sample were collected from each participant, performed liver function tests using the Enzyme-linked immunosorbent assay, and detected the Hepatitis B virus viral load and microRNA (101, 122) using quantitative polymerase chain reaction. Results: The results showed that 2^-ΔΔCT for miRNA-101 gene expression in HB patients under the treatment group was 0.4±0.3, in chronic carriers was 4.9±0.2, and in patients with occult HBV infection was 1.3±1.2, and the control group was 24.8 ± 1.3, the results revealed lower values than their control group with significant P=0.0422*, P=0.0120*, and P=0.01*, respectively. And miRNA-122 gene expression in HB patients under the treatment group was 0±0.001, in chronic carriers was 3.3±0.8, and in patients with occult HBV infection was 0.1±0.01, and the control group was 7±1.4, the results revealed lower values than their control group with significant P=0.001**, P=0.012*, and 0.010*, respectively. Conclusion: The miRNA-101 and 122 genes revealed downregulated compared to the control group during different clinical samples of HBV infection This confirms that decreased gene expression plays a role in causing hepatitis B virus infection. | ||||
| Keywords | ||||
| HBV infection; miRNA-101 and 122; Gene expression; Diyala province | ||||
|
Statistics Article View: 268 |
||||
